RITA I. JAIN, M.D.

Corporate Board Profile

Tech Score: 0/100

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2023-04-25	Rita I. Jain, M.D. 61 2023 3 Rita I. Jain, M.D. became a director of Celldex in February 2023. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Cheryl L. Cohen and Garry Neil, M.D. No compensation information provided for Rita I. Jain, M.D.
2024-04-25	Effective June 2022, Directors who are not our employees are each entitled to receive the lesser of 13,600 options or the number of options subject to the existing Director annual compensation limit of $400,000 and, for new directors, the lesser of 27,200 options or the number of options subject to the existing Director compensation limit of $600,000. In June 2023, all non-employee directors received an annual stock option grant to purchase 11,300 shares of the Company’s common stock following the 2023 Annual Meeting of Stockholders except Dr. Jain because she was just below the Director compensation limit of $600,000. In February 2023, when Dr. Jain joined the Board, she received a stock option grant to purchase 17,100 shares of the Company’s common stock. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).

Filing Date

Source Excerpt

2023-04-25

Rita I. Jain, M.D. 61 2023 3 Rita I. Jain, M.D. became a director of Celldex in February 2023. The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert J. Conrad, Chair, Cheryl L. Cohen and Garry Neil, M.D. No compensation information provided for Rita I. Jain, M.D.

2024-04-25

Effective June 2022, Directors who are not our employees are each entitled to receive the lesser of 13,600 options or the number of options subject to the existing Director annual compensation limit of $400,000 and, for new directors, the lesser of 27,200 options or the number of options subject to the existing Director compensation limit of $600,000. In June 2023, all non-employee directors received an annual stock option grant to purchase 11,300 shares of the Company’s common stock following the 2023 Annual Meeting of Stockholders except Dr. Jain because she was just below the Director compensation limit of $600,000. In February 2023, when Dr. Jain joined the Board, she received a stock option grant to purchase 17,100 shares of the Company’s common stock. ... The amounts in the Option Awards column reflect the grant date fair value in accordance with U.S. GAAP of stock option awards made in 2023 to each of our non-employee directors for awards pursuant to the 2021 Incentive Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of forfeiture (so long as the director remains a member of the Board as of such date).

Data sourced from SEC filings. Last updated: 2025-08-30